Is Apelvis covered by medical insurance? What is the price after medical insurance?

Alpelisib (Alpelisib) is an oral phosphatidylinositol 3-kinase (PI3K) inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women and men with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer who have progressed on endocrine-based regimens. Apelix 300 mg was administered daily concomitantly with intramuscular (IM) fulvestrant 500 mg on days 1, 15, and 29 and every 28 days thereafter. In order to control adverse drug reactions, it is allowed to reduce the dose of apelix to 250 mg or 200 mg daily.

Phosphatidylinositol-3-kinase-alpha (PI3Kα) is responsible for cell proliferation in response to activation of the growth factor-tyrosine kinase pathway. In some cancers, the p110α catalytic subunit of PI3Kα is mutated, making it overactive. ApelixinhibitsPI3K, with the highest specificity for PI3Kα. Apelix does not prolong the QTcF interval. Patients taking Apelvis experienced dose-dependent benefits from treatment, with a 51% advantage at the 200 mg daily dose over the 100 mg dose, and a 22% advantage at the once-daily 300 mg dose over the twice-daily 150 mg dose. This suggests that patients requiring lower doses may benefit from twice daily dosing.

However, the original drug of Apelvis has not yet been marketed in China, so it has not been included in the national medical insurance catalog, and its price after medical insurance is impossible to talk about. However, if the original drug Apelvis can be successfully launched in China in the future, based on its innovation and clinical value, it is expected to be included in the scope of national medical insurance reimbursement, thus providing financial support to more patients.